The authors of a study published in JAMA Cardiology assessed the relationship between growth in Medicaid expenditures and decreased mortality over a 15-year period.
Health improvements for patients with acute myocardial infarction (AMI) varied across hospitals and were associated with the diffusion of cost-effective care, rather than overall expenditure growth between 1999 and 2014, according to a new study.
Identifying a lack of research on the association between long-term growth in Medicare spending and health outcomes, the authors of the study published in JAMA Cardiology assessed the relationship between growth in Medicaid expenditures and decreased mortality over the 15-year period.
“There is little agreement regarding the association between healthcare expenditures and outcomes, with estimates ranging from large and positive to 0 and negative,” wrote the authors. “Although it is well understood that not all spending is cost-effective, nearly all studies have summarized the multidimensional components of patient care by a single dollar measure—total expenditures—rather than considering how the money is spent.”
The authors examined a longitudinal patient-level database from the Medicare fee-for-service population of elderly patients admitted to the hospital for AMI between January 1, 1999, and January 30, 2014. A random 20% sample of Medicare beneficiaries for 1999, 2000, and 2004 and a 100% sample for 2008, 2013, and 2014 were assessed. The authors combined 2 years of data for January 1, 1999, through December 31, 2000, and January 1, 2013, through June 30, 2014, in order to increase statistical power in smaller hospitals.
The cohort of 479,893 patients included those:
The 180-day, 30-day, and 31- to 180-day case fatality rates were assessed. Overall, 180-day case fatality rates declined from 26.9% in 1999-2000 to 21.5% in 2013-2014, with most of the decline due to the 30-day period. The 31- to 180-day fatality rate was not significantly changed between 1990-2000 and 2013-2014.
Overall inflation- and risk-adjusted 180-day mean expenditures per patient increased by 13% from 1999-2000 to 2013-2014; however, all of the increase had occurred by 2008. Total spending increased by 6.1% up to 30 days beyond the index admission and by 31% from 31 to 365 days beyond the index admission.
Mean expenditures in the 5.0% of hospitals (n  =  61) with the most rapid expenditure growth between 1999-2000 and 2013-2014 increased by 44.1% ($12,828 [SD = $2315]); for the 5.0% of hospitals with the slowest expenditure growth (n  =  61), mean expenditures decreased by 18.7% (−$7384 [$4141]; 95% CI, $8177-$6496).
Spending on cardiac procedures was positively associated with the 180-day mortality rate, whereas postacute care spending yielded moderate cost-effectiveness ($455,000 per life saved after 180 days; 95% CI, $323,000-$833,000).
“This moderation in spending observed for patients with AMI masks substantial and continued hospital variability with regard to growth or declines in overall spending, suggesting that local factors and not just national policy changes continue to be important components of expenditure growth,” concluded the authors.
Reference
Likosky DS, Van Parys J, Zhou W, Borden WB, Weinstein MC, Skinner JS. Association between Medicare expenditure growth and mortality rates in patients with acute myocardial infarction: a comparison from 1999 through 2014 [published online December 20, 2017]. JAMA Cardiol. doi: 10.1001/jamacardio.2017.4771.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Oz Confirmation Hearing Probes Vision for Medicaid but Coalesces Around Well-Being
March 14th 2025Mehmet Oz, MD, the nominee to lead CMS under the Trump administration, testified in a confirmation hearing before the Senate Finance Committee, where he found common ground on improving outcomes through healthier lifestyle choices but encountered repeated questions on potential Medicaid cuts.
Read More